
Eyenovia $EYEN stock falls 70% after unexpected results from the recent drug study
Eyenovia ($EYEN) said Friday that a phase 3 study evaluating its drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia, did not meet its primary endpoint.
The company's shares were down nearly 70% in recent trading.
The independent Data Review Committee found no significant difference in myopia progression between the treatment arms of 0.01% and 0.1% atropine and the placebo.
Eyenovia said it would terminate the study despite safety data indicating that all dosages and placebo were well-tolerated.
Source: MT Newswires